People · Operator
Named in public records as an officer, director or promoter · active 2006–2016 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aerie Pharmaceuticals Inc | — | Biotechnology | Series D+ | $189.6M | $5.2B | 2012 |
| Forty Seven, Inc. | — | Pharmaceuticals | Series C | $109.1M | $2.6B | 2015 |
| SARcode Corp | — | Biotechnology | Series C | $99.6M | $1.8B | 2006 |
| Humanigen, Inc | — | Pharmaceuticals | Series B | $39.2M | $16.8M | 2012 |
| Cleave Biosciences, Inc. | — | Biotechnology | Series B | $37.9M | $475.1M | 2016 |
DENNIS HENNER at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside DENNIS HENNER on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Root | 1 | 16 |
| Andrew Schwab | 1 | 16 |
| Peter Thompson | 1 | 16 |
| James Healy | 1 | 8 |
| Michael Harrison | 1 | 8 |
| Brian Levy | 1 | 8 |
| Jonathan MacQuitty | 1 | 7 |
| ANAND MEHRA | 1 | 7 |
| Carol Gallagher | 1 | 6 |
| Laura Shawver | 1 | 6 |
| Robert Alexander | 1 | 6 |
| Christopher Schaepe | 1 | 6 |
| Eric Jensen | 1 | 5 |
| David Epstein | 1 | 5 |
| Jeffrey Bird | 1 | 5 |
| Cameron Durrant | 1 | 5 |
| Brigitte Smith | 1 | 5 |
| Timothy Smith | 1 | 5 |
| Gerald Cagle | 1 | 4 |
| James Mazzo | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.